This event is approved for up to 26 credits by the Centre for Continuing Health Professional Education (CCHPE). The Centre for CCHPE, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Schools and through the (CACMS) is accredited to award AMA PRA category 1 credits.
This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.
Through a reciprocal agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Centre for CCHPE, Faculty of Medicine, McGill University designates this activity for AMA PRA Category 1 credit(s) up to the maximum number of credit hours noted above.
Each physician should claim only those hours of credit that he/she actually spent at the educational activity.
For more information about the CME Program and CME credits please contact Becca Isakower at bisakower@teratology.org.
Saturday, June 26, 2010 |
|
|
8:00 AM–11:30 AM |
Education Course Session 1 (Separate registration required)
Prenatal Drug Disposition and Teratogenesis
|
| |
|
| 8:00 AM–8:10 AM |
Welcome |
| |
Barbara F. Hales, Teratology Society President |
| |
|
| 8:10 AM–8:15 AM |
Course Overview |
| |
Education Committee Chairperson, Louise M. Winn, Queen’s University |
| |
|
| 8:15 AM–9:00 AM |
The Role of Biotransformation in Developmental Toxicology |
| |
Craig Harris, University of Michigan |
| |
(Learning Objective: A better understanding of the biotransformation pathways and processes found in the developing conceptus that are able to metabolize xenobiotics/teratogens and also regulate normal developmental processes.) |
| |
|
| 9:00 AM–10:00 AM |
Break |
| |
|
| 10:00 AM–10:45 AM |
Prenatal Ontogeny and Capabilities of Phase I and Phase II Enzymes |
| |
J. Steven Leeder, Children's Mercy Hospitals and Clinics |
| |
(Learning Objective: Understand the role of drug biotransformation processes in a developmental context and describe developmental patterns of expression for major Phase I and Phase II drug biotransformation pathways.) |
| |
|
| 10:45 AM–11:30 AM |
Repair Capabilities in the Embryo |
| |
Peter G. Wells, University of Toronto |
| |
(Learning Objective: A better understanding of DNA damage and repair in embryonic and fetal development.) |
| |
|
| 2:15 PM–4:45 PM |
Education Course Session 2 (Separate registration required)
Postnatal Drug Disposition and Teratogenesis |
| |
|
| 2:15 PM–3:00 PM |
Postnatal Metabolic Systems |
| |
Ronald N. Hines, Medical College of Wisconsin |
| |
(Learning Objective: A better understanding of the postnatal changes that occur in drug/toxicant metabolizing systems and how such changes might impact risk for adverse events.) |
| |
|
| 3:00 PM–4:00 PM |
Break |
| |
|
| 4:00 PM–4:45 PM |
Environmental Influences |
| |
Carl L. Keen, University of California, Davis |
| |
(Learning Objective: To understand the role that nutrition and other extrinsic factors may play in determining postnatal drug disposition and subsequent teratologic outcomes.) |
| |
|
Sunday, June 27, 2010 |
|
|
8:15 AM–9:15 AM |
Josef Warkany Lecture |
| |
50 Years of Progress in Understanding the Causes of Three Common Birth Defects |
| |
Diana M. Juriloff, University of British Columbia |
| |
(Learning Objective: A better understanding of the causes of some common birth defects.) |
| |
|
| 12:00 NOON–1:00 PM |
Joint TS/OTIS Box Lunch
Robert L. Brent Lecture |
| |
Ionizing Radiation Exposure to the Fetus and Infant from Medical Imaging: A Radiologist’s Perspective |
| |
Donald P. Frush, Duke University Medical Center |
| |
(Learning Objective: Become familiar with the controversial literature dealing with the risk of cancer in embryos/fetuses exposed to ionizing radiation.) |
| |
|
| 2:00 PM–3:00 PM |
Joint TS/ETS Exchange Lecture |
| |
Pros and Cons of the Extended-One-Generation Study Protocol |
| |
Teratology Society
The Cons of the Extended One-Generation Study Protocol
Paul M.D. Foster, National Institute of Environmental Health Sciences |
| |
(Learning Objective: To gain a better understanding of the regulatory requirements for reproductive toxicity testing.) |
| |
|
| |
European Teratology Society
The Extended One-Generation Reproduction Toxicity Study: Improving
Hazard Assessment and Saving Animals?
Aldert H. Piersma, National Institute for Public Health and the Environment (RIVM), Bilthoven |
| |
(Learning Objective: A better understanding of the impact of the design of reproductive toxicity study protocols on conclusions for hazard and risk assessment.) |
| |
|
| 3:15 PM–5:45 PM |
Vitamin B12 and Neural Tube Defects: Is It Time to Fortify Food with B12? Symposium |
| |
|
| 3:15 PM–3:40 PM |
Vitamin B12 Deficiency and NTDs: Is There a Causal Relationship? |
| |
James L. Mills, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH |
| |
(Learning Objective: To determine the relationship between maternal vitamin B12 levels and neural tube defects.) |
| |
|
| 3:40 PM–4:05 PM |
Normal Vitamin B12 Physiology, the Pathophysiology of B12 Deficiency, and Their Relevance to Treatment and Fortification |
| |
Ralph Carmel, New York Methodist Hospital and Weill Medical College of Cornell University |
| |
(Learning Objective: To understand how vitamin B12functions and what can cause vitamin B12 deficiency.) |
| |
|
| 4:05 PM–4:30 PM |
Should FDA Require Vitamin B12 Fortification of Enriched Flour? Yes |
| |
Godfrey P. Oakley, Emory University |
| |
(Learning Objective: To know that B12 fortification of flour would provide most of the population 50 and over with the 2.4 micrograms of synthetic vitamin B12 that is recommended by the Institute of Medicine/Food Nutrition Board and would prevent most, but not all, vitamin B12 deficiencies in this group.) |
| |
|
| 4:30 PM–4:55 PM |
Should We Fortify Food with B12 Now? No |
| |
Ralph Green, University of California Davis Medical Center |
| |
(Learning Objective: An improved understanding of the role of B12 in cellular function and the prevention of disease.) |
| |
|
| 4:55 PM–5:45 PM |
Panel Discussion and Response to Questions from the Audience |
| |
|
Monday, June 28, 2010 |
|
|
8:00 AM –9:00 AM |
State of the Art Lecture
Palate Development: Molecular Perspectives and Current Understanding |
| |
Robert M. Greene, University of Louisville |
| |
(Learning Objective: To present current scientific studies and knowledge on palate development.) |
| |
|
| 9:15 AM–11:45 AM |
Joint TS/OTIS/NBTS Symposium
Reproductive Psychiatry |
| |
|
| 9:15 AM–9:20 AM |
Introduction |
| |
|
| 9:20 AM–9:50 AM |
Prenatal SRI Exposure: Where Does Neonatal Behavioral Syndrome End and Neurobehavioral Teratogenicity Begin? |
| |
Tim F. Oberlander, University of British Columbia |
| |
(Learning Objectives: Appreciate the role serotonin plays in early brain development in children of mothers with antenatal mood disturbances treated with an SSRI antidepressant.) |
| |
|
| 9:50 AM–10:20 AM |
Messages from the Womb: Maternal Antidepressant Use and Fetal Neurobehavior |
| |
Amy L. Salisbury, Alpert Medical School of Brown University |
| |
(Learning Objectives: Participants will gain a better understanding of the potential effects of antidepressant medications on fetal neurobehavioral development.) |
| |
|
| 10:20 AM–10:50 AM |
An Update on Lithium Treatment during Pregnancy and Lactation |
| |
Adele C. Viguera, Neurological Institute, Cleveland Clinic |
| |
(Learning Objective: To share up to date information on lithium treatment for women during pregnancy and breast-feeding.) |
| |
|
| 10:50 AM–11:20 AM |
Effects of Developmental Exposure to Methylphenidate on Brain Areas Involved in Cognition, Motivated Behaviors, Appetite and Stress |
| |
Teresa Ann Milner, Weill Cornell Medical College |
| |
(Learning Objective: Participants will be provided with an understanding of the effects of exposure during development to methylphenidate on brain areas that regulate learning, behavior, appetite and response to stress.) |
| |
|
| 11:20 AM–11:45 AM |
Discussion: How Do We Incorporate These Data into Human Risk Assessment? |
| |
Katherine L. Wisner, University of Pittsburgh Medical Center |
| |
(Learning Objective: Participants will be offered a model of integrating complex risk/benefit data into decision making for the N=1 woman in the office.) |
| |
|
| 1:15 PM–2:15 PM |
Special Lecture
Human Teratogens: Update 2010 |
| |
Lewis B. Holmes, MassGeneral Hospital for Children |
| |
(Learning Objective: A better understanding of the exposures in pregnancy which can cause birth defects.) |
| |
|
| 2:15 PM–5:00 PM |
Update on Thalidomide Symposium |
| |
|
| 2:15 PM–2:20 PM |
Introduction |
| |
Lewis B. Holmes, MassGeneral Hospital for Children |
| |
|
| 2:20 PM–2:30 PM |
Thalidomide Epidemic and the Founding of the Teratology Society |
| |
F. Clarke Fraser, McGill University |
| |
(Learning Objectives: A better understanding of the thalidomide epidemic and the Teratology Society.) |
| |
|
| 2:30 PM–3:15 PM |
Thalidomide Embryopathy: Ophthalmologic Findings and a Few Surprises |
| |
Marilyn Miller, University of Illinois College of Medicine |
| |
(Learning Objectives: To better appreciate the ophthalmologic manifestations of thalidomide embryopathy.) |
| |
|
| 3:15 PM–3:30 PM |
Break |
| |
|
| 3:30 PM–4:15 PM |
Recent Advances in Understanding the Developmental Basis of Phocomelia |
| |
Patrick Allard, Harvard Medical School |
| |
(Learning Objectives: Understanding how thalidomide can lead to phocomelia.) |
| |
|
| 4:15 PM–5:00 PM |
Lessons Learned from the Thalidomide Epidemic and the Current Hypotheses of the Possible Mechanisms of Action |
| |
Trent Stephens, Idaho State University |
| |
(Learning Objectives: Attendees will be provided with an update and summary of thalidomide's history, including current issues and advances toward understanding its mechanism.) |
| |
|
Tuesday, June 29, 2010 |
|
|
7:00 AM–8:20 AM |
Sunrise Mini Course (Separate registration required)
Imaging Tools for Structural and Functional Teratogenesis Analyses |
| |
|
| 7:00 AM–7:40 AM |
Imaging Tools for Structural Analysis |
| |
William Slikker, Jr., National Center for Toxicological Research, U.S. FDA |
| |
(Learning Objectives: A better understanding of the use of imaging in preclinical safety assessment of potential developmental toxicants.) |
| |
|
| 7:40 AM–8:20 AM |
Imaging Tools for Functional Analysis |
| |
Julia M. Stephen, University of New Mexico |
| |
(Learning Objectives: To better understand the role of functional neuroimaging in teratology research.) |
| |
|
| 8:30 AM–9:15 AM |
TS/NBTS/OTIS Joint Special Lecture
Children's Environmental Health: A Good Start Lasts a Lifetime |
| |
Linda S. Birnbaum, National Institute of Environmental Health Sciences |
| |
(Learning Objectives: An understanding as to how environmental exposures during early development can have long term impacts on human health.) |
| |
|
| 9:30 AM–12:00 NOON |
Joint TS/NBTS Symposium
Advancing Neurodevelopmental Evaluation in Children:
An Interdisciplinary Approach |
| |
|
| 9:30 AM–9:55 AM |
The Use of Neurodevelopmental Data in Children in the Risk Assessment of Environmental Chemicals |
| |
Susan Makris, U.S. Environmental Protection Agency |
| |
(Learning Objectives: To provide information on, and better understanding of, the way in which neurodevelopmental data in children are useful in a risk assessment context for environmental toxicants.) |
| |
|
| 9:55 AM–10:20 AM |
A Multidisciplinary Approach to Advancing the Science of Neurodevelopmental Testing in Cohorts of Infants and Young Children |
| |
Judy S. LaKind, LaKind Associates, LLC |
| |
(Learning Objectives: A better understanding of the importance of a multi-disciplinary approach to conducting neurodevelopmental epidemiologic research on environmental exposures.) |
| |
|
| 10:20 AM–10:45 AM |
Getting the Biggest Bang for Your Buck: Choosing Neurodevelopmental Tests That Maximize Power |
| |
Lauren Kenworthy, George Washington University Medical School |
| |
(Learning Objectives: Participants will be able to identify key attributes of neurodevelopmental tests that increase their power and efficacy at measuring change.) |
| |
|
| 10:45 AM–11:10 AM |
Threats to Study Validity: The Flynn Effect, Examiner Drift, Confounders, Lost in Translation, and Other Important Considerations |
| |
Laura Gutermuth Anthony, George Washington University School of Medicine |
| |
(Learning Objectives: To better understand the important methodological issues to consider when choosing and using a neurodevelopmental test to examine the effects of teratogens.) |
| |
|
| 11:10 AM–11:35 AM |
Weight-of-the-Evidence Assessment in Neurodevelopmental Epidemiology: A Plea for Consistency |
| |
Michael Goodman, Emory University |
| |
(Learning Objectives: A better understanding of methodological and reporting differences in epidemiological studies.) |
| |
|
| 11:35 AM–12:00 NOON |
Panel Discussion |
| |
|
| 9:30 AM–12:00 NOON |
March of Dimes Symposium
Herbal Supplement Usage during Pregnancy |
| |
|
| 9:30 AM–10:00 AM |
Herbal Usage during Pregnancy: Teratology Society White Paper |
| |
Richard K. Miller, University of Rochester Medical Center |
| |
(Learning Objectives: To share up-to-date information on herbal preparations and their usage during pregnancy.) |
| |
|
| 10:00 AM–10:30 AM |
Herbal Products: Are They What They Claim to Be? |
| |
Henry M. Hess, University of Rochester Medical Center |
| |
(Learning Objectives: To provide information on the usage and potential effects of herbal preparations during pregnancy.) |
| |
|
| 10:30 AM–11:00 AM |
Are Herbal Preparations What are Claimed? |
| |
William R. Obermeyer, ConsumerLab.com |
| |
(Learning Objectives: To share information on the claims made by proponents of herbal usage) |
| |
|
11:00 AM–11:10 AM |
Herbal Drugs in Pregnancy: A Canadian Perspective
Gideon Koren, The Hospital for Sick Children
(Learning objectives: A better understanding of gestational safety to herbals, the complexicity of studying herbals' safety, and the new Canadian process of approval natural products.) |
|
|
11:10 AM–11:20 AM |
Traditional Chinese Medicine: Herbal Medicine Origins and Utilization in China
Robert L. Brent, Alfred I. duPont Hospital for Children
(Learning objectives: A better understanding of the ancient herbal medicines, the current approval process in China, and the toxic exposure risk in herbal products.) |
|
|
11:20 AM–11:30 AM |
Herbal Preparations: Are We at the Beginning of Regulations? The Situation in Europe and the Eastern Mediterranean Region
Asher Ornoy, Hebrew University Hadassah Medical School and Israeli Ministry of Health
(Learning Objectives: A better understanding of ???) |
|
|
| |
|
| 11:30 AM–12:00 NOON |
Panel Discussion of Position Paper and Topic |
| |
Patricia M. Bittner, U.S. Consumer Product Safety Commission, Chair, Public Affairs Committee |
| |
(Learning Objectives: A better understanding of the role of maternal nutrition in pregnancy on intrauterine fetal growth.) |
| |
|
Wednesday, June 30, 2010 |
|
|
8:00 AM–10:30 AM |
Wiley-Blackwell Symposium (Publications Committee)
Teratology Society: 50 Years Then to Now |
| |
|
| 8:00 AM–8:30 AM |
A Personal Perspective of Historical Events That Affected the Development and Maturation of the Society in the Past 50 Years |
| |
Robert L. Brent, Alfred I. duPont Hospital for Children |
| |
(Learning Objectives: A better understanding of the origins and spirit of the Teratology Society.) |
| |
|
| 8:30 AM–9:15 AM |
Clinical Teratology |
| |
Kenneth Lyons Jones, CTIS |
| |
(Learning Objectives: To present clinical research, and interventions in teratology.) |
| |
|
| 9:15 AM–10:00 AM |
Experimental Teratology: Scenes from the Last Fifty Years |
| |
William J. Scott, Jr., Cincinnati Children's Hospital Medical Center |
| |
(Learning Objectives: to learn from the past to focus future research.) |
| |
|
| 10:00 AM–10:30 AM |
Fast Forward to the Future: Where Will We Be? |
| |
Barbara F. Hales, McGill University |
| |
(Learning Objectives: To consider the opportunities and challenges facing birth defects research and the Teratology Society in the future.) |
| |
|
| 2:00 PM–4:30 PM |
ILSI-HESI Symposium
21st Century Developmental Toxicology |
| |
|
| 2:00 PM–2:30 PM |
Exposure Assessment in the 21st Century: Increased Reliance on Biomonitoring |
| |
Sean Hays, Summit Toxicology |
| |
|
| 2:45 PM–3:15 PM |
Pathway Profiling and Tissue Modeling Using ToxCast HTS Data |
| |
Thomas B. Knudsen, National Center for Computational Toxicology |
| |
(Learning Objectives: See how data from high-throughout screening assays is being used to understand developmental toxicity.) |
| |
|
| 3:15 PM–3:45 PM |
Computational Toxicology: From Data to Analyses to Applications |
| |
Ivan Rusyn, University of North Carolina at Chapel Hill |
| |
(Learning Objectives: A better understanding of the current advances in assessment of possible health risks of environmental agents.) |
| |
|
| 3:45 PM–4:30 PM |
Future Strategies for Developmental Toxicity Safety Assessment |
| |
Thomas Hartung, Johns Hopkins University Center for Alternatives to Animal Testing |
| |
(Learning Objectives: Improved prediction of effects of chemicals on human health by selection of models that are more mechanistically relevant.) |
| |
|